Spero Therapeutics Inc (NASDAQ:SPRO) Expected to Announce Earnings of -$1.04 Per Share

Share on StockTwits

Equities research analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to report ($1.04) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have provided estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($0.92). Spero Therapeutics reported earnings of ($0.60) per share during the same quarter last year, which would suggest a negative year over year growth rate of 73.3%. The business is expected to report its next earnings results on Thursday, March 12th.

On average, analysts expect that Spero Therapeutics will report full-year earnings of ($3.11) per share for the current financial year, with EPS estimates ranging from ($3.34) to ($2.94). For the next financial year, analysts forecast that the firm will post earnings of ($3.65) per share, with EPS estimates ranging from ($5.27) to ($3.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). The business had revenue of $4.64 million for the quarter, compared to the consensus estimate of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%.

SPRO has been the subject of a number of analyst reports. Oppenheimer lowered their target price on shares of Spero Therapeutics from $30.00 to $20.00 in a research note on Wednesday, October 2nd. Cowen reissued a “buy” rating on shares of Spero Therapeutics in a research note on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Spero Therapeutics in a research note on Wednesday. Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Janney Montgomery Scott initiated coverage on shares of Spero Therapeutics in a research note on Monday, September 9th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Spero Therapeutics presently has an average rating of “Buy” and a consensus target price of $23.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Novo Holdings A S bought a new stake in Spero Therapeutics in the second quarter valued at $5,363,000. BlackRock Inc. increased its stake in Spero Therapeutics by 56.0% in the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock valued at $7,559,000 after purchasing an additional 235,691 shares in the last quarter. Renaissance Technologies LLC increased its stake in Spero Therapeutics by 89.7% in the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock valued at $2,474,000 after purchasing an additional 101,600 shares in the last quarter. AWM Investment Company Inc. increased its stake in Spero Therapeutics by 6.4% in the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock valued at $6,887,000 after purchasing an additional 36,019 shares in the last quarter. Finally, State Street Corp increased its stake in Spero Therapeutics by 16.3% in the third quarter. State Street Corp now owns 197,226 shares of the company’s stock valued at $2,091,000 after purchasing an additional 27,695 shares in the last quarter. 48.36% of the stock is owned by institutional investors and hedge funds.

Shares of SPRO stock traded up $0.17 during trading hours on Friday, hitting $11.09. 59,684 shares of the company’s stock traded hands, compared to its average volume of 48,266. The stock’s 50 day simple moving average is $10.99 and its 200 day simple moving average is $10.85. The stock has a market cap of $210.60 million, a PE ratio of -4.27 and a beta of 2.10. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Recommended Story: What is Elliott Wave theory?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect Hallmark Financial Services, Inc.  Will Announce Quarterly Sales of $128.10 Million
Zacks: Analysts Expect Hallmark Financial Services, Inc. Will Announce Quarterly Sales of $128.10 Million
Miragen Therapeutics   Shares Down 8.1%
Miragen Therapeutics Shares Down 8.1%
Appian  Stock Price Down 6.7%
Appian Stock Price Down 6.7%
Hi-Crush  Stock Price Down 7.4%
Hi-Crush Stock Price Down 7.4%
Uniqure   Shares Down 7.9%
Uniqure Shares Down 7.9%
Collegium Pharmaceutical  Trading Down 7.9%
Collegium Pharmaceutical Trading Down 7.9%


© 2006-2020 Ticker Report